Trial Profile
Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Deep Vein Thrombosis (DVT).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Sep 2023
Price :
$35
*
At a glance
- Drugs Fondaparinux sodium (Primary) ; Heparin
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 26 Jan 2010 Actual patient number (39) added as reported by ClinicalTrials.gov.
- 26 Jan 2010 Actual end date (November 2009) added as reported by ClinicalTrials.gov.
- 26 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.